Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4291986 | 0.91 | ALDH1A1 (0.51) | ALDH1A1L3MBTL1CXCR3MAPTTDP1 | |
| SCHEMBL4889040 | 0.82 | HDAC1 (0.56) | ALDH1A1HDAC1LMNAHDAC8 | |
| SCHEMBL3866206 | 0.77 | CXCR3 (0.51) | CXCR3 | |
| SCHEMBL7166265 | 0.76 | ALDH1A1 (0.59) | ALDH1A1L3MBTL1MAPTTDP1HDAC1 | |
| SCHEMBL359248 | 0.76 | OTC (0.53) | TDP1 | |
| SCHEMBL3862303 | 0.76 | DPP7 (0.42) | ALDH1A1TDP1LMNA | |
| SCHEMBL24648927 | 0.75 | LMNA (0.62) | ALDH1A1L3MBTL1MAPTTDP1LMNA | |
| SCHEMBL2159293 | 0.74 | TDP1 (0.60) | ALDH1A1L3MBTL1MAPTTDP1LTA4H | |
| SCHEMBL19157632 | 0.73 | DPP7 (0.37) | ALDH1A1TDP1 | |
| SCHEMBL4327813 | 0.73 | LTA4H (0.60) | LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253166-A1 | Conjugation of Peptides | NOVO NORDISK A/S (DK) | 2009-10-08 | — | — | US | claimed |
| US-20090105134-A1 | C-Terminally Pegylated Growth Hormones | NOVO NORDISK A/S (DK) | 2009-04-23 | — | — | US | claimed |
| JP-2008531482-A | — | — | 2008-08-14 | — | — | JP | claimed |
| EP-1850878-A2 | C-TERMINALLY PEGYLATED GROWTH HORMONES | NOVO NORDISK A/S (DK) | 2007-11-07 | — | — | EP | claimed |
| US-20070111926-A1 | Conjugation of peptides | NOVO NORDISK A/S (DK) | 2007-05-17 | — | — | US | claimed |
| WO-2006084888-A2 | C-TERMINALLY PEGYLATED GROWTH HORMONES | NOVO NORDISK A/S (DK) | 2006-08-17 | — | — | WO | claimed |
| EP-1673464-A2 | CONJUGATION OF PEPTIDES | NOVO NORDISK A/S (DK) | 2006-06-28 | — | — | EP | claimed |
| WO-2005035553-A2 | CONJUGATION OF PEPTIDES | NOVO NORDISK A/S (DK) | 2005-04-21 | — | — | WO | claimed |
| US-20090253166-A1 | Conjugation of Peptides | NOVO NORDISK A/S (DK) | 2009-10-08 | — | — | US | disclosed |
| US-20090253166-A1 | Conjugation of Peptides | NOVO NORDISK A/S (DK) | 2009-10-08 | — | — | US | disclosed |
| US-20090253166-A1 | Conjugation of Peptides | NOVO NORDISK A/S (DK) | 2009-10-08 | — | — | US | disclosed |
| US-7524813-B2 | Selectively conjugated peptides and methods of making the same | NOVO NORDISK HEALTH CARE AG (CH) | 2009-04-28 | — | — | US | disclosed |
| US-7524813-B2 | Selectively conjugated peptides and methods of making the same | NOVO NORDISK HEALTH CARE AG (CH) | 2009-04-28 | — | — | US | disclosed |
| US-7524813-B2 | Selectively conjugated peptides and methods of making the same | NOVO NORDISK HEALTH CARE AG (CH) | 2009-04-28 | — | — | US | disclosed |
| US-20070111926-A1 | Conjugation of peptides | NOVO NORDISK A/S (DK) | 2007-05-17 | — | — | US | disclosed |
| US-20070111926-A1 | Conjugation of peptides | NOVO NORDISK A/S (DK) | 2007-05-17 | — | — | US | disclosed |
| US-20070111926-A1 | Conjugation of peptides | NOVO NORDISK A/S (DK) | 2007-05-17 | — | — | US | disclosed |
| WO-2006084888-A2 | C-TERMINALLY PEGYLATED GROWTH HORMONES | NOVO NORDISK A/S (DK) | 2006-08-17 | — | — | WO | disclosed |
| EP-1673464-A2 | CONJUGATION OF PEPTIDES | NOVO NORDISK A/S (DK) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005035553-A2 | CONJUGATION OF PEPTIDES | NOVO NORDISK A/S (DK) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105134-A1 | C-Terminally Pegylated Growth Hormones | GHRHR, GHITM, HDGF | ALDH1A1 3531/4885L3MBTL1 1194/4885CXCR3 2737/4885 |
| US-20070111926-A1 | Conjugation of peptides | DNPEP, ENPEP, ANPEP | ALDH1A1 2226/4885L3MBTL1 2884/4885CXCR3 3276/4885 |
| US-20090253166-A1 | Conjugation of Peptides | DNPEP, ENPEP, ANPEP | ALDH1A1 2226/4885L3MBTL1 2884/4885CXCR3 3276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.